Arcturus Therapeutics Holdings Earnings Call Transcripts
Fiscal Year 2026
-
The company is refocusing on rare diseases with its mRNA platform, advancing ARCT-810 for OTC deficiency and ARCT-032 for cystic fibrosis. Regulatory clarity for pediatric trials is expected in Q2 2024, and the cash runway extends into Q2 2028, with additional funding likely needed for late-stage trials.
-
Recent progress includes well-tolerated phase II CF dosing, early efficacy signals, and a 12-week study with expanded endpoints and sites. The OTC program is prioritizing pediatric development, pending FDA guidance. KOSTAIVE vaccine approvals continue, with financial runway into Q2 2028, excluding arbitration outcomes.
-
Advanced mRNA therapeutics for rare diseases are progressing, with a pivotal phase IIb CF trial starting soon and regulatory clarity for the OTC deficiency program expected in the first half of the year. Strong financials support a focused, lean operation.
-
The company is advancing innovative mRNA therapies for cystic fibrosis and OTC deficiency, with strong interim clinical data and regulatory milestones targeted for 2026. Financial stability supports key studies and ongoing platform innovation.
Fiscal Year 2025
-
ARCT-032 and ARCT-810 mRNA programs advanced, with ARCT-032 entering a 12-week phase II study and ARCT-810 moving toward pivotal trials. Revenue and R&D expenses declined year-over-year, and cash runway now extends into Q2 2028.
-
Q3 revenue and expenses declined year-over-year, with a net loss of $13.5M. ARCT-032 and ARCT-810 programs advanced, while Kostaive's US launch faces regulatory delays. Cash runway extends into 2028, supporting global trial expansion.
-
Advanced CF and OTC programs with positive interim data and regulatory progress; revenue and expenses declined year-over-year, extending cash runway into 2028. Key vaccine programs and leadership changes support a strong outlook.
-
ARCT-810 demonstrated significant reductions in glutamine and increases in ureagenesis, indicating improved urea cycle function and metabolic control in OTC deficiency. The therapy was well tolerated, with robust biomarker data supporting its potential as a transformative treatment.
-
Prioritized CF and OTC programs, reduced costs, and extended cash runway to Q1 2028. Q1 2025 revenue declined year-over-year as KOSTAIVE transitioned to commercialization, with EU approval triggering a milestone payment. Interim data for key programs expected mid-2025.
-
The company is advancing its inhaled mRNA therapy for CF, targeting patients unresponsive to modulators, with phase 2 data expected soon. Its LUNAR platform offers differentiated, biodegradable delivery, and the financial runway extends into 2027. Key catalysts include multiple clinical and regulatory milestones.
-
The discussion highlighted a novel mRNA therapy targeting unmet needs in cystic fibrosis, with early clinical data showing safety and positive trends in lung function. The ongoing phase II trial focuses on patients not benefiting from current modulators, with interim results expected by mid-2025.
-
The conference highlighted advances in mRNA vaccine and therapeutic platforms, with a stabilized COVID vaccine market and strategic partnerships driving future revenue. Key updates are expected for cystic fibrosis and OTC deficiency programs, with pivotal data readouts anticipated next quarter.
-
The company highlighted its mRNA platform and delivery technology, with key Phase II data for CF and OTC programs expected in the first half of 2024. The CF program targets patients unresponsive to modulators, with a significant market opportunity if successful.
-
Significant progress was highlighted, including commercial launch of Kostaive in Japan, anticipated European approval, and robust clinical pipeline with two flagship programs nearing Phase 2 readouts. Strategic partnerships and manufacturing expansion position the company for a pivotal 2025.
Fiscal Year 2024
-
European approval of Costive and progress in CF and OTC programs marked a transformative year, with revenues down due to lower milestones but a strong cash position and multiple clinical readouts expected in 2025. Cash runway extends to Q1 2027, excluding future Costive revenues.
-
Significant momentum is expected in 2025 with expanded COVID vaccine sales in Japan and Europe, pivotal CF and OTC data readouts, and a strong cash position through Q1 2027. Regulatory and commercial partnerships are set to drive growth and platform validation.
-
The conference highlighted differentiated mRNA technology, strong clinical progress in CF and OTC programs, and robust partnerships driving commercialization. Key data readouts and regulatory milestones are expected in the first half of next year.
-
Kostaive, the first commercial product, launched in Japan, triggering a $25M milestone. Q3 revenue was $41.7M with a net loss of $6.9M, and cash runway extends into Q1 2027. Interim phase 2 data for key mRNA therapeutics is expected in H1 2025.
-
Self-amplifying mRNA and LUNAR delivery platforms offer lower-dose, durable vaccines and therapeutics. The CF program advances to phase II after positive safety and lung function data, while the COVID vaccine launches in Japan with global expansion planned. Key milestones include new clinical data, regulatory progress, and commercial launches.
-
The presentation highlighted next-generation mRNA vaccine and therapeutic platforms, with imminent commercial launches in Japan and Europe, strong clinical data, and robust global partnerships. Key milestones include new data releases and expansion into pandemic preparedness.
-
The session highlighted imminent regulatory approvals and commercial launches for the COVID-19 vaccine in Japan and Europe, with significant revenue and milestone payments expected. Key clinical data for COVID, flu, cystic fibrosis, and OTC deficiency programs are anticipated in the coming months, supporting a robust pipeline and financial outlook.
-
Key programs are advancing with strong partnerships, robust IP, and innovative mRNA technology. KOSTAIVE is set for commercial launch in Japan and Europe, supported by new manufacturing capacity and strategic government backing. Phase II and III trials across the pipeline are on track, with significant milestone and royalty potential.
-
Q2 2024 revenue surged to $49.9M, driven by CSL milestones and pandemic flu progress, while net loss narrowed to $17.2M. Kostaive's Japan launch is on track for Q4, with strong phase III data and manufacturing milestones achieved. Cash runway extends through Q1 2027.